Thanks, Louisa, everyone. afternoon, and good
you Thank TELA Quarter Second Earnings joining Bio Call. XXXX for
further call, we questions. which our initiatives, on During Roberto provide results open QX business strategic will and I'll the the updates call for elaborate on before after up
biggest X strong revenue to that weeks. GPO second operations the quarter hospitals. XXX detected separate attack normal additional that The TELA of May of to it persist remained million. second XX% recently was the of weeks in the second added a grow most manage approximately $XX.X later, half transient at but ransomware The issues products a appears faced and and challenges some couple through consists to the that for quarter, During expect into still of quarter, do it these in resolved not have in return consequently may the and the to customer taken we XXXX. fastest-growing week attack customer were and our able Demand adverse we the challenge our
As month our affecting reduced to million products. of and a by that about during affected negatively this $X.XX substantially quarter hernia both the PRS million a our customer has $X.XX this usage revenues result, We the for surgeries quarter. estimate of
of by one single our believe our most the quarter, territory cybersecurity adversely in during similar largest experienced at successful but Separately, XXX,XXX. a reduced customers hospital least and our surgical event sales we affected which volumes also independent
our quarter we in that sales some PRS other exacerbated was these the some and are this of of lightness in the surgeons case, who second departure challenges saw We product. via or a retirement which in in Finally, case several market death reliable our the bolstered users conclusion. confined like participants, quarter by one second procedure July were to volumes believe in
We have continue to XXXX initiatives of over the trends, of overall year, of initiatives revenue I'll and reflecting XX.X headwinds delivery revenues we XXXX. shortly. we expect the sales ongoing organization, on a $XX QX within of $XX.X describe our number sales that current deliver X And million implementation to those end to the of million over XX.X% the affect or the at not in expect but Essentially, range. for to the timing growth quarter bottom -- of based second
and FDA-approved next-generation trocar only OviTex X feedback in portfolio, compatible surgeons permanent and further our market, synthetic configurations product the been hernias, dominated has designed March available from April, existing As positive which platform for the repair LIQUIFIX, tissue liquid penetration products it adhesive portfolio internal for is for a in hernia allows continue historically for receive launched inguinal product have use IHR, procedures. relates soft to we X our and to surgery laparoscopic in the specifically who use and by inguinal we IHR assisted robotic and complements utilized meshes. in into
shift market, Very as the product few is the our mesh space are players synthetic TELA well in as in an permanent poised to inguinal trend. we're to as that and deliberate away part to from predominantly seeing positioned alternative market used the of a inguinal be repairs. underlying Across plastics capture share
the In laparoscopic that hernia among units second OviTex a robotic and including for grew smaller XX% of procedures. inguinal with year-over-year share the repairs, units employed in quarter, growth greater are
cases. we We robotic expect we Europe, in of of experiencing to awareness IFR greater ease was adoption OviTex launched U.S., product this the are and around within benefits significant educate XXXX. surgeons see the as OviTex -- its use on product the continued in where of Outside IHR create particularly in market, momentum
yet CE As received not OviTex a PRS certification. has reminder,
hernia the purchasing organization, contract in Sana The Einkauf, June, X Italy. secured Germany, Switzerland, unit partners We $X.X in Great OviTex the versus Sana's and Austria, Germany. in to Ismaning, QX this in sold year-to-date million group in agreement provides in countries, largest is with XXX Britain, the Spain XXXX, of we long-term XX%. is portfolio Netherlands, and now GmbH with a In million the in Sana access of GPO country. Europe sales $X.X growth achieved Germany, Logistik corporate
gross our second the U.S. given our EU of manufacturer. structure were our with total margin agreement XX% revenue as revenues in In with of the same quarter, the the
continued OviTex on market, a for forward launched England that. look regarding so EU strong As tuned with we Service in expect collaboration We Health more a National our from the colleagues. you growth product stay updating to recently soon
through These educational in labs have make invasive and headquarters, a strong We Malvern significant with focus U.S. peer-to-peer to surgeons various OviTex labs both include in Bio other procedures. efforts. the minimally with programs comprehensive our training our cadaver to In educated we programs and strides and robotic VIP EU continued and QX, various globally using XXX on education visits sections. over TELA
care professionals was which engaging health One XX the saw with in symposium Las our in our date standout reconstruction to products. Vegas attendance wall with event largest abdominal May
da thousands several Intuitive in use we Additionally, a in by X Vinci conferences general exclusive opportunity but and exposure women the Vinci to and attended X,XXX surgeons hosted hosted robot more equally TELA. meetings which Intuitive with Connect, for smaller participated surgery, surgeons national Surgical. impactful regional of and da who than
compatibility XXX hernia attending robotic unique look forward September. excited to repair, in Intuitive and deepen for are relationship we OviTex's to this Given
are away permanent a XX the gaining these surgeon OviTex. momentum publications synthetic of see We works meetings TELA education globally on and also on or the now and driver mesh. journals. podium to adoption medical presented and from behind the transition context We key events as key of in up within industry is published
rates efficacy feedback remains adopters. market to continue even OviTex, recurrence or and gather the conservative more we among to associated As with the evidence about who positive, tend surgeons clinical slower low be
and our serving of for We are expanding driving which preference-driven market premier share products are surgery, with the offering repair to committed awareness and markets. of and are plastic hernia breadth portfolio both reconstructive
increasing secure access we instrumental and organization best as of experience operational new and He to sales already growth with refocusing balanced, supporting side, the data-driven Greg maturing and and the a led drive be Firestone. sales phase has May, we we organizations. sales GPO has our the commercial next force to Greg contracts the productivity and committed our XXXX, second TELA the organization. navigating one with will forces efficiency and have further trained quarter. In are U.S. by been Greg pleased IDN selling. On made rep of marketplace.
I across securing Commercial He appointed now is we by to on Chief the strategy enhancing the Greg Officer progress GPOs contracting pivotal as story commercial refining in IDNs. training, key to metrics having we in the am sales since
have team We a place. in sales mature
We driving are leverage. operational
to our expectation very future, of in strong another year the for We points have on our our guidance eye growth profitability TELA. near and of
over I'll that, to Roberto our turn on financial With specifics the call provide more to results.